« Back
Home /
TICAM1 Antibody - C-terminal region

TICAM1 Antibody - C-terminal region

Item no.	OABB01048
Manufacturer	AVIVA Systems Biology
Amount	100 ug/vial
Category	Oncology Neuroscience Neural Lineage Markers Antibodies By Cell Type Hematology Leukemia Lymphoma Immunohistochemistry Western Blot ELISA Immunofluorescence Primary Antibodies Immunostaining
Type	Antibody Polyclonal
Format	Liquid
Applications	IF, IHC, ELISA
Specific against	Human (Homo sapiens)
Host	Rabbit
Isotype	IgG
Conjugate/Tag	Unconjugated
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	ADCADN;AIM;CXXC9;CXXC-type zinc finger protein 9;DNA (cytosine-5)-methyltransferase 1;DNA (cytosine-5-)-methyltransferase 1;DNA methyltransferase HsaI;DNA MTase HsaI;DNMT;HSN1E;m.HsaI;MCMT.
Available
Manufacturer - Type	Polyclonal Antibody
Manufacturer - Category	Root Catalog/Products/Polyclonal Antibodies, Root Catalog/Products/Primary Antibodies
Gene symbol	DNMT1
Gene Fullname	DNA methyltransferase 1
Product format	Liquid
Reconstitution and storage	-20°C or -80°C
Description of target	TICAM(TIR DOMAIN-CONTAINING ADAPTOR MOLECULE 1), also known as TICAM1 or TRIF, is an adapter in responding to activation of toll-like receptors(TLRs). It mediates the rather delayed cascade of two TLR-associated signaling cascades, where the other one is dependent upon a MyD88 adapter. By genomic sequence analysis, Oshiumi et al.(2003) mapped the TICAM1 gene to chromosome 19p13.3. By coimmunoprecipitation analysis, Oshiumi et al.(2003) showed that TICAM1 interacts specifically with TLR3, but not with other TLRs. Functional analysis showed that the association of TLR3 and TICAM1 mediates dsRNA activation of IFNB, through either NFKB, AP1, or IRF3. TICAM1 activation of NFKB was found to occur predominantly through IRAK1 rather than IRAK2. Small interfering(si)RNA blockage of TICAM1, just upstream of the TIR domain, reduced IFNB production in response to dsRNA.
Protein name	DNA (cytosine-5)-methyltransferase 1
Clonality	Recombinant Monoclonal
Purification	Affinity Purified
Immunogen	A synthesized peptide derived from human Dnmt1
Dilution	Methylates CpG residues. Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is essential for epigenetic inheritance. Associates with chromatin during G2 and M phases to maintain DNA methylation independently of replication. It is responsible for maintaining methylation patterns established in development. DNA methylation is coordinated with methylation of histones. Mediates transcriptional repression by direct binding to HDAC2. In association with DNMT3B and via the recruitment of CTCFL/BORIS, involved in activation of BAG1 gene expression by modulating dimethylation of promoter histone H3 at H3K4 and H3K9. Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells (PubMed:24623306). Also required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs) (PubMed:24623306). Associates at promoter regions of tumor suppressor genes (TSGs) leading to their gene silencing (PubMed:24623306). Promotes tumor growth (PubMed:24623306).

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

OABB01048-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 100 ug/vial

available

Delivery expected until 11/13/2025

Express Delivery: Save 8 days

Compare

Add to wishlist

Get an offer